Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human BAY 3713372 in MTAP-deleted solid tumors
2025-520623-24-00Phase 2Authorised
- Sponsor
- Bayer
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of BAY 3713372 in Nonhematologic neoplasms and methylthioadenosine phosphorylase deficiency (8 arms), sponsored by Bayer. Primary endpoints: Number of participants with treatment-emergent adverse events, Number of participants with treatment-emergent serious adverse events and 7 more. Planned start Nov 2025; status: authorised.
02
Drugs
BAY 3713372
03
Conditions
Nonhematologic neoplasmsmethylthioadenosine phosphorylase deficiency
Beyond the preview
Go deeper on 2025-520623-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520623-24-00.